易明医药(002826) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥160,425,522.45, a decrease of 6.42% compared to ¥171,430,742.25 in the same period last year[4] - Net profit attributable to shareholders increased by 233.58% to ¥27,899,079.55 from ¥8,363,504.12 year-on-year[4] - The net profit after deducting non-recurring gains and losses decreased by 77.30% to ¥1,779,975.38 from ¥7,841,904.72 in the previous year[4] - Basic earnings per share rose by 275.00% to ¥0.15 from ¥0.04 year-on-year[5] - Operating profit for Q1 2024 increased significantly to ¥32,394,318.88, compared to ¥10,698,166.47 in Q1 2023, representing a growth of 202.5%[24] - Net profit for Q1 2024 was ¥28,050,728.06, up from ¥8,478,872.65 in the previous year, marking a year-on-year increase of 230.5%[24] - The total comprehensive income for Q1 2024 is CNY 28,096,256.96, compared to CNY 8,391,700.71 in the same period last year, reflecting a substantial increase[25] Cash Flow - Operating cash flow for the quarter was ¥53,738,523.14, an increase of 68.84% compared to ¥31,828,337.43 in the same period last year[4] - The net cash flow from operating activities increased by 68.84% year-on-year, reaching RMB 53,738,523.14[10] - Cash inflow from operating activities totals CNY 202,042,040.04, down from CNY 224,475,914.77 in the previous year, a decrease of approximately 10%[27] - The net cash flow from operating activities is CNY 53,738,523.14, an increase from CNY 31,828,337.43 in Q1 2023, showing a growth of about 69%[27] - The company's cash and cash equivalents decreased by RMB 125.38 million, mainly due to investments in financial products[10] - Cash and cash equivalents at the end of Q1 2024 were ¥260,480,491.38, down from ¥385,855,732.02 at the beginning of the period, a decrease of 32.5%[21] - The cash and cash equivalents at the end of Q1 2024 stand at CNY 260,480,491.38, compared to CNY 207,346,181.35 at the end of Q1 2023, reflecting an increase of about 26%[28] Assets and Liabilities - Total assets at the end of the quarter were ¥938,542,851.11, a slight increase of 1.16% from ¥927,743,602.85 at the end of the previous year[5] - Total assets as of March 31, 2024, were ¥938,542,851.11, compared to ¥927,743,602.85 at the beginning of the year, an increase of 1.0%[22] - Total liabilities increased to ¥184,117,447.63 from ¥177,684,381.37, representing a rise of 3.0%[23] Operating Costs and Expenses - The company's operating costs decreased by 33.20% to ¥63,768,724.72 from ¥95,466,688.58 year-on-year[9] - Total operating costs for Q1 2024 were ¥155,954,093.91, down 4.3% from ¥163,151,787.75 year-on-year[24] - The cost of sales decreased by 33.20% compared to the same period last year, attributed to a decline in revenue from third-party cooperative products[10] - Sales expenses increased by 36.55% year-on-year, driven by investments in self-operated product promotion and marketing team development[10] - Management expenses rose by 47.52% year-on-year, mainly due to organizational optimization and safety fee provisions[10] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 20,339[12] - The company repurchased a total of 4,000,000 shares, accounting for 2.0978% of the total share capital, with a total expenditure of RMB 24,494,404.63[15] Government Support - The company received government subsidies amounting to ¥28,699,016.90, primarily related to operational support[7] - The company received RMB 28,185,000 in industry support funds during the reporting period, contributing to the increase in net cash flow from operating activities[10] Research and Development - Research and development expenses decreased by 45.67% to ¥270,814.38 from ¥498,451.91 in the previous year[9] Audit Status - The company has not undergone an audit for the Q1 2024 report[29]